Membranous Nephropathy Comprehensive Autoantibody Panel
Also known as: MNCA PAN
Use
The Membranous Nephropathy Comprehensive Autoantibody Panel is recommended for the evaluation of patients at risk for membranous nephropathy, specifically primary membranous glomerulonephritis (pMGN). The presence of Phospholipase A2 Receptor (PLA2R) IgG and THSD7A IgG antibodies can support this diagnosis in conjunction with other laboratory and clinical findings.
Special Instructions
Not provided.
Limitations
This test has not been cleared or approved by the FDA and was developed, and its performance characteristics determined by ARUP Laboratories in a CLIA certified laboratory. It is intended for clinical purposes. Antibody titers provide a semi-quantitative measurement and interpretation must be combined with clinical and other laboratory findings. Hemolyzed, hyperlipemic, icteric, heat-treated or contaminated specimens are unacceptable.
New York Approved
Methodology
Immunoassay (Indirect Fluorescent Antibody (IFA))
Biomarkers
LOINC Codes
- 82991-1 - PLA2R IgG SerPl Ql IF
- 93339-0 - THSD7A IgG SerPl Ql IF
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.2 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Collect blood in a Serum Separator Tube (SST).
Storage Instructions
Refrigerated storage is required.
Causes for Rejection
Hemolyzed, hyperlipemic, icteric, heat-treated or contaminated specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 month |
Other tests from different labs that may be relevant